Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.

Delpech, Y; Coutant, C; Hsu, L; Barranger, E; Iwamoto, T; Barcenas, C H; Hortobagyi, G N; Rouzier, R; Esteva, F J; Pusztai, L

Delpech, Y; Coutant, C; Hsu, L; Barranger, E; Iwamoto, T; Barcenas, C H; Hortobagyi, G N; Rouzier, R; Esteva, F J; Pusztai, L.

Affiliation

Delpech Y; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Br J Cancer ; 108(2): 285-91, 2013 Feb 05.

Article in En | MEDLINE | ID: mdl-23299541

Subject(s)

Breast Neoplasms/drug therapy; Carcinoma, Ductal, Breast/drug therapy; Carcinoma, Lobular/drug therapy; Neoadjuvant Therapy; Adult; Aged; Aged, 80 and over; Breast Neoplasms/mortality; Breast Neoplasms/pathology; Breast Neoplasms/surgery; Carcinoma, Ductal, Breast/mortality; Carcinoma, Ductal, Breast/pathology; Carcinoma, Ductal, Breast/surgery; Carcinoma, Lobular/mortality; Carcinoma, Lobular/pathology; Carcinoma, Lobular/surgery; Chemotherapy, Adjuvant; Female; Humans; Mastectomy, Segmental; Middle Aged; Receptors, Estrogen/metabolism; Treatment Outcome; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Carcinoma, Lobular / Carcinoma, Ductal, Breast / Neoadjuvant Therapy Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Br J Cancer Year: 2013 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google